Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P180028/S019

HeartStart FRx Defibrillator (861304)

PHILIPS MEDICAL SYSTEMS · Decision date May 21, 2026

FDA DECISIONP180028/S019

What did the FDA approve?

FDA records P180028/S019 as a supplement to PMA P180028, with the supplement type “Real-Time Process”. The recorded decision is approval, dated May 21, 2026.

FDA approval order statement

a new adhesive material used in the electrode pads.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
May 21, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P180028/S019
Regulatory pathway
PMA supplement
Product code
MKJ
Decision code
APPR
Decision date
May 21, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Automated external defibrillators (non-wearable).

Product code
MKJ
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P180028/S017 · Related supplement

    HeartStart FRx Defibrillator and HeartStart SMART Pads II

  2. P180028/S018 · Related supplement

    HeartStart FRx Defibrillator

  3. P180028/S019 received

    Application receipt date recorded by FDA.

  4. P180028/S019 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P180028. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P180028

Product / regulatory recordCompanyPathwayDecision dateSource
PHILIPS MEDICAL SYSTEMSPMA supplementSep 5, 2025FDA
PHILIPS MEDICAL SYSTEMSPMA supplementFeb 2, 2026FDA

Explore the linked device profile

Other records with product code MKJ

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

PHILIPS MEDICAL SYSTEMS

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
22100 Bothell Everett Hwy., Bothell, WA, 98021

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records